4
Aug
2022
Alnylam’s Big Day, Amgen Buys ChemoCentryx & a Borisy Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2022
ElevateBio, Boston Children’s Form Startup to Turn iPSCs Into Mature T-cells for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Aug
2022
A Glimpse Into the Adjacent Possible: Incorporating AI Into Medical Science
The implementation of emerging technologies requires front-line users to figure out what to do with the technology – how to adapt the technology to the problems users are actively trying to solve. The most impactful use cases often are not immediately obvious – for example, Edison envisioned the phonograph would be predominantly used to record wills. Moreover, effective adoption typically requires... Read More
26
Jul
2022
The New Frontier of Cytokine Therapies: Engineered Selectivity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jul
2022
CAMP4 Raises $100M to Drug ‘the Dark Side of the Genome’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Jul
2022
James Mutamba of Arrakis on Negotiating a Big Amgen Deal at Warp Speed
James Mutamba is the chief business officer of Waltham, Mass.-based Arrakis Therapeutics. It’s a biotech developing small molecules against RNA targets. Arrakis struck its first major pharma partnership in 2020 with Roche. During the JP Morgan Healthcare Conference this past January, Arrakis announced another multi-target collaboration with Amgen to discover and develop small molecule RNA degraders, a new drug class... Read More
14
Jul
2022
Novavax Cleared, Verve’s Gene Editing Milestone, & Third Rock Reaches Out
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jul
2022
Restoring Eyesight in the Developing World: Dr. Sanduk Ruit on The Long Run
Today’s guest on The Long Run is Dr. Sanduk Ruit. He is an ophthalmologist and the founder and executive director of the Tilganga Institute of Ophthalmology. The institute is in Kathmandu, Nepal. Dr. Ruit has restored the eyesight of more than 130,000 people in Asia and Africa. He’s the pioneer of a small-incision form of cataract surgery. Not only was... Read More
10
Jul
2022
Innovators Require An Exception-Oriented Mindset
Living in innovative domains like biomedical research requires an appreciation for the exceptional, the outlier. You might even argue that the goal of innovators – at least those who hope to see their ideas gain acceptance, or their inventions adopted – is to institutionalize the exceptional and make it routine. In the Perez model of technology adoption, this is the... Read More
7
Jul
2022
Merck Circles Seagen, Arch Triples Down & Novartis Cuts 8,000 Jobs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jul
2022
An Open Letter from Female Biotech Leaders on Post-Roe America
[Editor’s Note: this letter was drafted by female biotech leaders in response to the Supreme Court’s Dobbs decision. It was co-signed by more than 65 female biotech executives as of July 1. They’re listed at the end.] Friends and colleagues, legislators and elected officials We join the resounding millions in chorus to express our profound dismay and disappointment at the... Read More
29
Jun
2022
Recode Therapeutics Pockets Extra $120M for Targeted Genetic Medicine Delivery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Jun
2022
How Grace Science Built a Community Into a Company
Matt Wilsey, CEO of Grace Science, once said, “You may have a plan set out for your career and your family, but life doesn’t always turn out that way…you have to make the most of it…turn the lemons into lemonade.” It is a fitting description for a person who has made several shifts on a quest to cure a rare... Read More
27
Jun
2022
Nucleate Doubles in Size, Enabling Young Scientists’ Entrepreneurial Dreams
Academia has a tradition of doing nothing, or next to nothing, to educate and encourage young people to learn about entrepreneurship. But whether academia wants it or not, it’s coming. Young scientists are taking matters into their own hands, organizing themselves in many major research hubs. Nucleate, the nonprofit providing free resources to empower a new generation of biotech entrepreneurs,... Read More
27
Jun
2022
What We Saw at BIO: The Second Hurdle
More than 14,000 people attended the annual #BIO22 meeting in San Diego, meaning there are at least 14,000 versions of what happened. But unless you have the emotional intelligence of a rock, you felt the unease, if not outright panic, of an industry with a fast-evaporating cash runway. No one really knows what to do about it. If they say... Read More
26
Jun
2022
Women’s Rights Are Under Attack, and Biotech Can Respond
On Friday night, after the Supreme Court’s decision to overturn Roe vs. Wade, my extended family gathered around my mother’s dining table. We were supposed to be there to celebrate my 18-year-old niece’s graduation from high school. We ended up talking late into the night, discussing the implications of the Court’s majority opinion which will greatly restrict access to safe... Read More
23
Jun
2022
Clinical Trials That Deliver Better Social and Financial Returns
Sometimes doing the right thing requires sacrifice. Other times, the right thing for human health can also be a shrewd business move. That was the intriguing result of a study on the returns sponsors can expect from decentralized trials. The study relied on data from Medable and the Tufts Center for the Study of Drug Development. Results were presented this... Read More
22
Jun
2022
Bringing Precision Medicine to Neuro: Ivana Magovcevic-Liebisch on The Long Run
Today’s guest on The Long Run is Ivana Magovcevic-Liebisch She is the CEO of Cambridge, Mass.-based Vigil Neuroscience. The story starts with Amgen. The big biotech made a strategic decision to get out of neuroscience in 2019. That meant a couple of drug programs targeting TREM2 came up for sale. One is a monoclonal antibody, and the other is a... Read More
21
Jun
2022
Why Kymab Agreed to be Acquired by Sanofi
UK-based Kymab made headlines back in January 2021. Sanofi agreed to acquire the antibody drug developer for $1.1 billion upfront, plus $350 million in potential milestones. The main attraction for Sanofi was KY1005, a monoclonal antibody targeting OX40L, a regulator of the immune system. Five months before the deal, Kymab announced it hit both primary endpoints of a Phase 2a... Read More
16
Jun
2022
Day One Shines, Third Rock Carries On and Vertex/CRISPR Deliver
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.